Gilead’s shares rose 3.1% after earnings, with investors responding to 16% year-over-year growth in base business sales and a $1.6 billion increase to 2026 base business revenue guidance over the course of the year. The quarter’s growth was led by HIV, though some of the sequential HIV sales increase reflected inventory dynamics that management expects to normalize by year-end.
Shares in Gilead moved modestly higher by 0.5% following the quarter, reflecting a broadly in-line result with no major surprises or disappointments despite raised HIV growth guidance.
Gilead’s shares fell 3.6% following earnings as investors reacted negatively to cautious near-term guidance implied by sequential sales declines and typical first-quarter seasonality, signaling deceleration despite solid year-over-year growth in key HIV products.
Gilead Sciences delivered robust third-quarter results, highlighting strong growth across its HIV portfolio and disciplined cost management, leading to a 22% year-over-year increase in non-GAAP EPS.